Additive Effect of Endonase on Eradication Rate of Second Line Therapy for HP Infection

• Status: Terminated
• Trial end date: 2013-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Endonase, a kind of protease, is known to cause both extensive degradation of mucins and a reduction in mucus viscosity. As part of the search for more effective forms of therapy against H. pylori when it colonizes not only the surface of the surface mucosal cells but also the surface mucous gel layer covering the mucosal surface of the stomach. The investigators decided to investigate whether or not endonase might have additive effect of pronase on the efficacy of the second-line eradication therapy against Helicobacter pylori.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chuncheon Sacred Heart Hospital

Criteria

Inclusion Criteria:

Patients with 18 years or more of age AND Patients who failed the standard proton pump inhibitor-based triple therapy for H. pylori

Exclusion Criteria:

1. Patients Under 18 years, OR

2. Patients with active peptic ulcer, OR

3. Pregnant or Breast feeding women, OR

4. Patients with gastric malignancy, OR

5. Patients with a history of drug allergy or hypersensitivity, OR

6. Patients with severe renal, liver, or heart diseases